230 related articles for article (PubMed ID: 15791460)
41. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma.
Cox C; Teknos TN; Barrios M; Brewer GJ; Dick RD; Merajver SD
Laryngoscope; 2001 Apr; 111(4 Pt 1):696-701. PubMed ID: 11359142
[TBL] [Abstract][Full Text] [Related]
42. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
Hu L; Hofmann J; Holash J; Yancopoulos GD; Sood AK; Jaffe RB
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6966-71. PubMed ID: 16203789
[TBL] [Abstract][Full Text] [Related]
43. Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of fusaric acid and paclitaxel or carboplatin.
Jaglowski JR; Stack BC
Cancer Lett; 2006 Nov; 243(1):58-63. PubMed ID: 16412572
[TBL] [Abstract][Full Text] [Related]
44. Opioids and migration, chemotaxis, invasion, and adhesion of human cancer cells.
Zagon IS; Rahn KA; McLaughlin PJ
Neuropeptides; 2007 Dec; 41(6):441-52. PubMed ID: 17910895
[TBL] [Abstract][Full Text] [Related]
45. Effects of combination treatment of bortezomib and dexamethasone in SCCHN cell lines depend on tumor cell specificity.
Wagenblast J; Baghi M; Arnoldner C; Bisdas S; Gstöttner W; May A; Knecht R; Hambek M
Oncol Rep; 2008 Nov; 20(5):1207-11. PubMed ID: 18949423
[TBL] [Abstract][Full Text] [Related]
46. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
[TBL] [Abstract][Full Text] [Related]
47. The anticancer activity of the transcription inhibitor terameprocol (meso-tetra-O-methyl nordihydroguaiaretic acid) formulated for systemic administration.
Lopez RA; Goodman AB; Rhodes M; Blomberg JA; Heller J
Anticancer Drugs; 2007 Sep; 18(8):933-9. PubMed ID: 17667599
[TBL] [Abstract][Full Text] [Related]
48. Hyaluronic acid-paclitaxel conjugate inhibits growth of human squamous cell carcinomas of the head and neck via a hyaluronic acid-mediated mechanism.
Galer CE; Sano D; Ghosh SC; Hah JH; Auzenne E; Hamir AN; Myers JN; Klostergaard J
Oral Oncol; 2011 Nov; 47(11):1039-47. PubMed ID: 21903450
[TBL] [Abstract][Full Text] [Related]
49. Inositol hexaphosphate and paclitaxel: symbiotic treatment of oral cavity squamous cell carcinoma.
Janus SC; Weurtz B; Ondrey FG
Laryngoscope; 2007 Aug; 117(8):1381-8. PubMed ID: 17607147
[TBL] [Abstract][Full Text] [Related]
50. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model.
Kang HJ; Lee SH; Price JE; Kim LS
Breast J; 2009; 15(3):223-9. PubMed ID: 19645775
[TBL] [Abstract][Full Text] [Related]
51. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.
Langer CJ; Harris J; Horwitz EM; Nicolaou N; Kies M; Curran W; Wong S; Ang K
J Clin Oncol; 2007 Oct; 25(30):4800-5. PubMed ID: 17947728
[TBL] [Abstract][Full Text] [Related]
52. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
McLaughlin PJ; Zagon IS
Biochem Pharmacol; 2012 Sep; 84(6):746-55. PubMed ID: 22687282
[TBL] [Abstract][Full Text] [Related]
53. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
[TBL] [Abstract][Full Text] [Related]
54. Regulation of human head and neck squamous cell carcinoma growth in tissue culture by opioid growth factor.
McLaughlin PJ; Levin RJ; Zagon IS
Int J Oncol; 1999 May; 14(5):991-8. PubMed ID: 10200353
[TBL] [Abstract][Full Text] [Related]
55. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
[TBL] [Abstract][Full Text] [Related]
56. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec).
Oertel S; Krempien R; Lindel K; Zabel A; Milker-Zabel S; Bischof M; Lipson KE; Peschke P; Debus J; Abdollahi A; Huber PE
Strahlenther Onkol; 2006 Jul; 182(7):400-7. PubMed ID: 16826359
[TBL] [Abstract][Full Text] [Related]
57. Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts.
Vink SR; Lagerwerf S; Mesman E; Schellens JH; Begg AC; van Blitterswijk WJ; Verheij M
Clin Cancer Res; 2006 Mar; 12(5):1615-22. PubMed ID: 16533789
[TBL] [Abstract][Full Text] [Related]
58. Prevention of local tumor growth with paclitaxel-loaded microspheres.
Azouz SM; Walpole J; Amirifeli S; Taylor KN; Grinstaff MW; Colson YL
J Thorac Cardiovasc Surg; 2008 May; 135(5):1014-21. PubMed ID: 18455578
[TBL] [Abstract][Full Text] [Related]
59. Anti-tumor activity of heptaplatin in combination with 5-fluorouracil or paclitaxel against human head and neck cancer cells in vitro.
Lee JW; Park JK; Lee SH; Kim SY; Cho YB; Kuh HJ
Anticancer Drugs; 2006 Apr; 17(4):377-84. PubMed ID: 16549994
[TBL] [Abstract][Full Text] [Related]
60. Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.
McLaughlin PJ; Zagon IS; Park SS; Conway A; Donahue RN; Goldenberg D
BMC Cancer; 2009 Oct; 9():369. PubMed ID: 19835629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
